Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Approved-not yet active				18 and over				Other				CICL670A2412-HMO-CTIL NCT00452660


2.		Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-Dependent Iron Overload

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Active				18 and over				Pharmaceutical / Industry				CICL670ADE03 NCT00481143


3.		Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-Thalassaemia Patients) With Chronic Iron Overload

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care				Active				18 to 80				Pharmaceutical / Industry				CICL670AHU02 NCT00564941


4.		Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Diagnostic, Supportive care				Active				16 and over				Pharmaceutical / Industry				CICL670AAU01 NCT00673608


5.		Safety, Tolerability, and Efficacy of Deferasirox in MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 and over				Other				MDS0306 NCT00469560

First Published: 1/23/2008


6.		Phase II Pilot Study of Deferasirox in Patients With Transfusional Iron Overload After Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Active				18 to 70 years old at transplantation				NCI, Pharmaceutical / Industry				UMN-2007LS065 2007LS065, UMN-MT2007-11R, NOVARTIS-CICL670AUS12, NCT00602446


7.		Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Active				10 and over				Pharmaceutical / Industry				CICL670A2206 NCT00600938

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute